Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
出版年份 2016 全文链接
标题
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
作者
关键词
-
出版物
LEUKEMIA
Volume 30, Issue 8, Pages 1701-1707
出版商
Springer Nature
发表日期
2016-05-24
DOI
10.1038/leu.2016.148
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children
- (2014) R. Masetti et al. HAEMATOLOGICA
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
- (2014) G Barosi et al. LEUKEMIA
- Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context
- (2014) Nicholas R. Latimer et al. MEDICAL DECISION MAKING
- Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
- (2014) Hans C Hasselbalch Expert Review of Hematology
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma
- (2012) P. Korhonen et al. Journal of Biopharmaceutical Statistics
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now